Filtros : "Clinical Therapeutics" Limpar

Filtros



Refine with date range


  • Source: Clinical Therapeutics. Unidades: FOB, FMRP

    Subjects: FÁRMACOS, ANTIDEPRESSIVOS, HEMORRAGIA, SISTEMA GASTROINTESTINAL

    PrivadoAcesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      FORGERINI, Marcela et al. Use of antidepressants and the risk of upper gastrointestinal tract bleeding: a case-control study. Clinical Therapeutics, v. 45, n. 7, p. e159-e166, 2023Tradução . . Disponível em: https://doi.org/10.1016/j.clinthera.2023.04.010. Acesso em: 17 maio 2024.
    • APA

      Forgerini, M., Schiavo, G., Urbano, G., Nadai, T. R. de, Zapata-Cachafeiro, M., Herdeiro, M. T. F., & Mastroianni, P. de C. (2023). Use of antidepressants and the risk of upper gastrointestinal tract bleeding: a case-control study. Clinical Therapeutics, 45( 7), e159-e166. doi:10.1016/j.clinthera.2023.04.010
    • NLM

      Forgerini M, Schiavo G, Urbano G, Nadai TR de, Zapata-Cachafeiro M, Herdeiro MTF, Mastroianni P de C. Use of antidepressants and the risk of upper gastrointestinal tract bleeding: a case-control study [Internet]. Clinical Therapeutics. 2023 ; 45( 7): e159-e166.[citado 2024 maio 17 ] Available from: https://doi.org/10.1016/j.clinthera.2023.04.010
    • Vancouver

      Forgerini M, Schiavo G, Urbano G, Nadai TR de, Zapata-Cachafeiro M, Herdeiro MTF, Mastroianni P de C. Use of antidepressants and the risk of upper gastrointestinal tract bleeding: a case-control study [Internet]. Clinical Therapeutics. 2023 ; 45( 7): e159-e166.[citado 2024 maio 17 ] Available from: https://doi.org/10.1016/j.clinthera.2023.04.010
  • Source: Clinical Therapeutics. Unidades: FCF, FM

    Subjects: QUEIMADURAS, FARMACODINÂMICA, FARMACOCINÉTICA, SEPSE

    Versão PublicadaAcesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      MESSIANO, Claudia Garcia et al. Therapeutic target attainment of 3-Hour extended Infusion of Meropenem in patients with septic burns. Clinical Therapeutics, v. 44, p. 624-629, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.clinthera.2022.02.007. Acesso em: 17 maio 2024.
    • APA

      Messiano, C. G., Morales Júnior, R., Pereira, G. O., Silva Junior, E. M. da, Gomez, D. de S., & Santos, S. R. C. J. (2022). Therapeutic target attainment of 3-Hour extended Infusion of Meropenem in patients with septic burns. Clinical Therapeutics, 44, 624-629. doi:10.1016/j.clinthera.2022.02.007
    • NLM

      Messiano CG, Morales Júnior R, Pereira GO, Silva Junior EM da, Gomez D de S, Santos SRCJ. Therapeutic target attainment of 3-Hour extended Infusion of Meropenem in patients with septic burns [Internet]. Clinical Therapeutics. 2022 ; 44 624-629.[citado 2024 maio 17 ] Available from: https://doi.org/10.1016/j.clinthera.2022.02.007
    • Vancouver

      Messiano CG, Morales Júnior R, Pereira GO, Silva Junior EM da, Gomez D de S, Santos SRCJ. Therapeutic target attainment of 3-Hour extended Infusion of Meropenem in patients with septic burns [Internet]. Clinical Therapeutics. 2022 ; 44 624-629.[citado 2024 maio 17 ] Available from: https://doi.org/10.1016/j.clinthera.2022.02.007
  • Source: Clinical Therapeutics. Unidade: FMRP

    Subjects: GLAUCOMA, HIPERTENSÃO OCULAR, MEDICAMENTO

    Versão PublicadaAcesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      BELFORT JUNIOR, Rubens et al. Fixed-combination bimatoprost/brimonidine/timolol in glaucom: a randomized, masked, controlled, phase III study conducted in Brazil. Clinical Therapeutics, v. 42, n. 2, p. 263-275, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.clinthera.2019.12.008. Acesso em: 17 maio 2024.
    • APA

      Belfort Junior, R., Paula, J. S., Silva, M. J. L., Della Paolera, M., Kim, T., Chen, M. Y., & Goodkin, M. L. (2020). Fixed-combination bimatoprost/brimonidine/timolol in glaucom: a randomized, masked, controlled, phase III study conducted in Brazil. Clinical Therapeutics, 42( 2), 263-275. doi:10.1016/j.clinthera.2019.12.008
    • NLM

      Belfort Junior R, Paula JS, Silva MJL, Della Paolera M, Kim T, Chen MY, Goodkin ML. Fixed-combination bimatoprost/brimonidine/timolol in glaucom: a randomized, masked, controlled, phase III study conducted in Brazil [Internet]. Clinical Therapeutics. 2020 ; 42( 2): 263-275.[citado 2024 maio 17 ] Available from: https://doi.org/10.1016/j.clinthera.2019.12.008
    • Vancouver

      Belfort Junior R, Paula JS, Silva MJL, Della Paolera M, Kim T, Chen MY, Goodkin ML. Fixed-combination bimatoprost/brimonidine/timolol in glaucom: a randomized, masked, controlled, phase III study conducted in Brazil [Internet]. Clinical Therapeutics. 2020 ; 42( 2): 263-275.[citado 2024 maio 17 ] Available from: https://doi.org/10.1016/j.clinthera.2019.12.008
  • Source: Clinical Therapeutics. Unidades: FCF, FM

    Subjects: FARMACOCINÉTICA, FARMACODINÂMICA, PLASMA

    Acesso à fonteAcesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      OLIVEIRA, Maura Salaroli de et al. Pharmacokinetic and pharmacodynamic characteristics of vancomycin and meropenem in critically Ill patients receiving sustained lowefficiency dialysis. Clinical Therapeutics, v. 42, p. N. 4 625-633, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.clinthera.2020.02.011. Acesso em: 17 maio 2024.
    • APA

      Oliveira, M. S. de, Machado, A. S., Mendes, E. T., Chaves, L., Perdigão Neto, L. V., Silva Junior, C. V. da, et al. (2020). Pharmacokinetic and pharmacodynamic characteristics of vancomycin and meropenem in critically Ill patients receiving sustained lowefficiency dialysis. Clinical Therapeutics, 42, N. 4 625-633. doi:10.1016/j.clinthera.2020.02.011
    • NLM

      Oliveira MS de, Machado AS, Mendes ET, Chaves L, Perdigão Neto LV, Silva Junior CV da, Santos SRCJ, Sanches C, Macedo E, Levin ASS. Pharmacokinetic and pharmacodynamic characteristics of vancomycin and meropenem in critically Ill patients receiving sustained lowefficiency dialysis [Internet]. Clinical Therapeutics. 2020 ; 42 N. 4 625-633.[citado 2024 maio 17 ] Available from: https://doi.org/10.1016/j.clinthera.2020.02.011
    • Vancouver

      Oliveira MS de, Machado AS, Mendes ET, Chaves L, Perdigão Neto LV, Silva Junior CV da, Santos SRCJ, Sanches C, Macedo E, Levin ASS. Pharmacokinetic and pharmacodynamic characteristics of vancomycin and meropenem in critically Ill patients receiving sustained lowefficiency dialysis [Internet]. Clinical Therapeutics. 2020 ; 42 N. 4 625-633.[citado 2024 maio 17 ] Available from: https://doi.org/10.1016/j.clinthera.2020.02.011
  • Source: Clinical Therapeutics. Unidade: FCFRP

    Subjects: SEGURANÇA DO PACIENTE, FÁRMACOS, FARMACOVIGILÂNCIA, MEDICAMENTO

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      VARALLO, Fabiana Rossi et al. Harmonization of pharmacovigilance regulation in Brazil: opportunities to improve risk communication. Clinical Therapeutics, v. 41, n. 3, p. 598-603, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.clinthera.2019.01.013. Acesso em: 17 maio 2024.
    • APA

      Varallo, F. R., Forgerini, M., Herdeiro, M. T. F., & Mastroianni, P. de C. (2019). Harmonization of pharmacovigilance regulation in Brazil: opportunities to improve risk communication. Clinical Therapeutics, 41( 3), 598-603. doi:10.1016/j.clinthera.2019.01.013
    • NLM

      Varallo FR, Forgerini M, Herdeiro MTF, Mastroianni P de C. Harmonization of pharmacovigilance regulation in Brazil: opportunities to improve risk communication [Internet]. Clinical Therapeutics. 2019 ; 41( 3): 598-603.[citado 2024 maio 17 ] Available from: https://doi.org/10.1016/j.clinthera.2019.01.013
    • Vancouver

      Varallo FR, Forgerini M, Herdeiro MTF, Mastroianni P de C. Harmonization of pharmacovigilance regulation in Brazil: opportunities to improve risk communication [Internet]. Clinical Therapeutics. 2019 ; 41( 3): 598-603.[citado 2024 maio 17 ] Available from: https://doi.org/10.1016/j.clinthera.2019.01.013
  • Source: Clinical Therapeutics. Unidades: FCF, FM

    Subjects: ANTIBIÓTICOS, DOENÇAS INFECCIOSAS

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      MACHADO, Anna Silva et al. Clinical outcome and antimicrobial therapeutic drug monitoring for the treatment of infections in acute burn patients. Clinical Therapeutics, v. 39, n. 8, p. 1649-1657, 2017Tradução . . Disponível em: https://doi.org/10.1016/j.clinthera.2017.06.008. Acesso em: 17 maio 2024.
    • APA

      Machado, A. S., Oliveira, M. S., Sanches, C., Silva Junior, C. V. da, Gomez, D. S., Gemperli, R., et al. (2017). Clinical outcome and antimicrobial therapeutic drug monitoring for the treatment of infections in acute burn patients. Clinical Therapeutics, 39( 8), 1649-1657. doi:10.1016/j.clinthera.2017.06.008
    • NLM

      Machado AS, Oliveira MS, Sanches C, Silva Junior CV da, Gomez DS, Gemperli R, Santos SRCJ, Levin ASS. Clinical outcome and antimicrobial therapeutic drug monitoring for the treatment of infections in acute burn patients [Internet]. Clinical Therapeutics. 2017 ; 39( 8): 1649-1657.[citado 2024 maio 17 ] Available from: https://doi.org/10.1016/j.clinthera.2017.06.008
    • Vancouver

      Machado AS, Oliveira MS, Sanches C, Silva Junior CV da, Gomez DS, Gemperli R, Santos SRCJ, Levin ASS. Clinical outcome and antimicrobial therapeutic drug monitoring for the treatment of infections in acute burn patients [Internet]. Clinical Therapeutics. 2017 ; 39( 8): 1649-1657.[citado 2024 maio 17 ] Available from: https://doi.org/10.1016/j.clinthera.2017.06.008
  • Source: Clinical Therapeutics. Conference titles: Conference of the European Association for Clinical Pharmacology and Therapeutics (EACPT). Unidades: FMRP, FCFRP

    Subjects: FARMACOCINÉTICA, FARMACOLOGIA, CONVULSÕES

    How to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      ANTUNES, Natalícia de Jesus et al. Influence of verapamil on the pharmacokinetics of oxcarbazepine and 10-hydroxycarbazepine enantiomers in healthy volunteers. Clinical Therapeutics. Bridgewater: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. . Acesso em: 17 maio 2024. , 2013
    • APA

      Antunes, N. de J., Wichert-Ana, L., Coelho, E. B., Pasqua, O. D., Alexandre Júnior, V., Takayanagui, O. M., & Lanchote, V. L. (2013). Influence of verapamil on the pharmacokinetics of oxcarbazepine and 10-hydroxycarbazepine enantiomers in healthy volunteers. Clinical Therapeutics. Bridgewater: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo.
    • NLM

      Antunes N de J, Wichert-Ana L, Coelho EB, Pasqua OD, Alexandre Júnior V, Takayanagui OM, Lanchote VL. Influence of verapamil on the pharmacokinetics of oxcarbazepine and 10-hydroxycarbazepine enantiomers in healthy volunteers. Clinical Therapeutics. 2013 ; 35( 85): e76.[citado 2024 maio 17 ]
    • Vancouver

      Antunes N de J, Wichert-Ana L, Coelho EB, Pasqua OD, Alexandre Júnior V, Takayanagui OM, Lanchote VL. Influence of verapamil on the pharmacokinetics of oxcarbazepine and 10-hydroxycarbazepine enantiomers in healthy volunteers. Clinical Therapeutics. 2013 ; 35( 85): e76.[citado 2024 maio 17 ]
  • Source: Clinical Therapeutics. Unidade: FCF

    Subjects: BIOEQUIVALÊNCIA, FARMACOCINÉTICA, CROMATOGRAFIA LÍQUIDA DE ALTA EFICIÊNCIA

    Acesso à fonteHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      SILVA, Marina de Freitas et al. Bioequivalence evaluation of single doses of two tramadol formulations: a randomized, open-label, two-period crossover study in healthy Brazilian volunteers. Clinical Therapeutics, v. 32, n. 4, p. 758-765, 2010Tradução . . Disponível em: http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B6VRS-4YYPPM6-H-1&_cdi=6242&_user=5674931&_pii=S0149291810001074&_orig=browse&_coverDate=04%2F30%2F2010&_sk=999679995&view=c&wchp=dGLzVzz-zSkzS&md5=39b0f577aa141d4e2b40edd118fdd7a3&ie=/sdarticle.pdf. Acesso em: 17 maio 2024.
    • APA

      Silva, M. de F., Schramm, S. G., Kano, E. K., Koono, E. E. M., Porta, V., & Serra, C. H. dos R. (2010). Bioequivalence evaluation of single doses of two tramadol formulations: a randomized, open-label, two-period crossover study in healthy Brazilian volunteers. Clinical Therapeutics, 32( 4), 758-765. Recuperado de http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B6VRS-4YYPPM6-H-1&_cdi=6242&_user=5674931&_pii=S0149291810001074&_orig=browse&_coverDate=04%2F30%2F2010&_sk=999679995&view=c&wchp=dGLzVzz-zSkzS&md5=39b0f577aa141d4e2b40edd118fdd7a3&ie=/sdarticle.pdf
    • NLM

      Silva M de F, Schramm SG, Kano EK, Koono EEM, Porta V, Serra CH dos R. Bioequivalence evaluation of single doses of two tramadol formulations: a randomized, open-label, two-period crossover study in healthy Brazilian volunteers [Internet]. Clinical Therapeutics. 2010 ; 32( 4): 758-765.[citado 2024 maio 17 ] Available from: http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B6VRS-4YYPPM6-H-1&_cdi=6242&_user=5674931&_pii=S0149291810001074&_orig=browse&_coverDate=04%2F30%2F2010&_sk=999679995&view=c&wchp=dGLzVzz-zSkzS&md5=39b0f577aa141d4e2b40edd118fdd7a3&ie=/sdarticle.pdf
    • Vancouver

      Silva M de F, Schramm SG, Kano EK, Koono EEM, Porta V, Serra CH dos R. Bioequivalence evaluation of single doses of two tramadol formulations: a randomized, open-label, two-period crossover study in healthy Brazilian volunteers [Internet]. Clinical Therapeutics. 2010 ; 32( 4): 758-765.[citado 2024 maio 17 ] Available from: http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B6VRS-4YYPPM6-H-1&_cdi=6242&_user=5674931&_pii=S0149291810001074&_orig=browse&_coverDate=04%2F30%2F2010&_sk=999679995&view=c&wchp=dGLzVzz-zSkzS&md5=39b0f577aa141d4e2b40edd118fdd7a3&ie=/sdarticle.pdf
  • Source: Clinical Therapeutics. Unidade: FCF

    Subjects: BIOEQUIVALÊNCIA, ZIDOVUDINA (FARMACOCINÉTICA)

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      SERRA, Cristina Helena dos Reis et al. Bioequivalence and pharmacokinetics of two zidovudine formulations in healthy Brazilian volunteers: an open-label, randomized, single-dose, two-way crossover study. Clinical Therapeutics, v. 30, n. 5, p. 902-908, 2008Tradução . . Disponível em: https://doi.org/10.1016/j.clinthera.2008.05.003. Acesso em: 17 maio 2024.
    • APA

      Serra, C. H. dos R., Koono, E. E. M., Kano, E. K., Schramm, S. G., Armando, Y. P., & Porta, V. (2008). Bioequivalence and pharmacokinetics of two zidovudine formulations in healthy Brazilian volunteers: an open-label, randomized, single-dose, two-way crossover study. Clinical Therapeutics, 30( 5), 902-908. doi:10.1016/j.clinthera.2008.05.003
    • NLM

      Serra CH dos R, Koono EEM, Kano EK, Schramm SG, Armando YP, Porta V. Bioequivalence and pharmacokinetics of two zidovudine formulations in healthy Brazilian volunteers: an open-label, randomized, single-dose, two-way crossover study [Internet]. Clinical Therapeutics. 2008 ;30( 5): 902-908.[citado 2024 maio 17 ] Available from: https://doi.org/10.1016/j.clinthera.2008.05.003
    • Vancouver

      Serra CH dos R, Koono EEM, Kano EK, Schramm SG, Armando YP, Porta V. Bioequivalence and pharmacokinetics of two zidovudine formulations in healthy Brazilian volunteers: an open-label, randomized, single-dose, two-way crossover study [Internet]. Clinical Therapeutics. 2008 ;30( 5): 902-908.[citado 2024 maio 17 ] Available from: https://doi.org/10.1016/j.clinthera.2008.05.003

Digital Library of Intellectual Production of Universidade de São Paulo     2012 - 2024